Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
This study used NMA and DA to explore EGFR-TKI-related AEs. Drugs varied in AE profiles, mostly mild, but Osimertinib and Dacomitinib were associated with more severe events. Osimertinib carried a high cardiac risk, delayed onset, and high mortality. Thus, comprehensive patient assessment and close monitoring are crucial with EGFR-TKI use.
Authors
- Xinya Liu (ORCID: https://orcid.org/0000-0001-7813-3151)
- Li‐Ling Wu (ORCID: https://orcid.org/0000-0002-2293-6999)
- Yun Jiang (ORCID: https://orcid.org/0009-0003-3020-8574)
- Jian Yu
- Mengjiao Gao
- Jiawei Li (ORCID: https://orcid.org/0000-0002-4018-0830)
- Yuanming Zhang (ORCID: https://orcid.org/0000-0001-6208-6469)
- Ting Chai
- Jing Shi (ORCID: https://orcid.org/0009-0004-9767-3486)
Institutions
- Xinjiang Medical University (CN)
- Fifth Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3389/fphar.2025.1519849
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04